-
Capital, M&A & Industry Strategy1 week agoAstellas and AI Proteins sign miniprotein therapeutics deal
Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m to design and optimise de novo miniproteins directed at...
-
Capital, M&A & Industry Strategy1 week agoCritical decisions that spurred these 40 Under 40 winners to success
Securing financing that allowed an exit from academia, leaving ecology and evolutionary biology for biomedical engineering and shifting from business development to entrepreneurship are among key...
-
Capital, M&A & Industry Strategy1 week agoAptaDir: Switching silenced genes back on with targeted demethylation
BIOCENTURY | EMERGING COMPANY PROFILEAPTADIR: SWITCHING SILENCED GENES BACK ON WITH TARGETED DEMETHYLATIONMilan-based biotech raised a €40M seed round to take RNA-DNA chimeras into the clinic,...
-
Capital, M&A & Industry Strategy1 week agoChina’s IIT overhaul has narrowed access and raised standards
BIOCENTURY | PRODUCT DEVELOPMENTCHINA’S IIT OVERHAUL HAS NARROWED ACCESS AND RAISED STANDARDSInvestigators report a sharp drop in study approvals under Order 818 but see benefits for...
-
Capital, M&A & Industry Strategy1 week agoArcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
-
Capital, M&A & Industry Strategy1 week agoThe 6 biggest crossover rounds in biopharma history
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.
-
Capital, M&A & Industry Strategy1 week agoChina’s licensing deals soar as US biotechs enjoy a bumper M&A year
China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to...
-
Capital, M&A & Industry Strategy1 week agoIronwood promoting commercial chief in planned CEO succession
BIOCENTURY | MANAGEMENT TRACKSIRONWOOD PROMOTING COMMERCIAL CHIEF IN PLANNED CEO SUCCESSIONPlus: Former Novo CEO to become Lundbeck’s chair; FDA official takes position amid BetaNova merger; and...
-
Capital, M&A & Industry Strategy1 week agoRoche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration
The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Hansoh’s ADC...
-
Capital, M&A & Industry Strategy1 week agoTakara Bio USA, SPT Labtech Team Up to Automate NGS Library Prep Workflows
The partners are targeting NGS core labs with a combined offering that automates next-generation sequencing library prep workflows using kits from Takara Bio and SPT Labtech’s...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
